C4 Imaging

C4 Imaging is an innovative medical device company founded in 2009, specializing in personalized patient treatment through accurate image-guided procedures. The company's core proprietary technology, C4, is a unique magnetic resonance imaging (MRI) agent encapsulated within an implantable, biocompatible shell. Their flagship product, the Sirius™ MRI Marker, is designed to facilitate seed localization during prostate cancer treatment. This marker enables physicians to accurately locate seeds within the complex anatomy of the prostate and surrounding critical structures using a single post-implant MR imaging procedure. C4 Imaging's ultimate goal is to enhance quality assurance by allowing post-implant seed localization to be performed with MRI alone, eliminating the need for computed tomography in the assessment of prostate brachytherapy. The company recently secured a $1.03M Venture Round investment on 01 March 2024, signaling confidence from potential backers in its pioneering approach to improving medical imaging and cancer treatment within the Hardware and Health Care industries.